ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saadjian, A.
Right arrow Articles by Arnaud, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saadjian, A.
Right arrow Articles by Arnaud, A.
Eur Respir J 1994; 7: 862-868
Copyright © ERS Journals Ltd 1994

Clinical Trial

Effect of almitrine bismesylate on pulmonary vasoreactivity to hypoxia in chronic obstructive pulmonary disease

AY Saadjian, FF Philip-Joel, A Barret, S Levy, and AG Arnaud

The aim of this double-blind, placebo-controlled study was to determine whether acute administration of almitrine enhances hypoxic pulmonary vasoconstriction in patients with chronic obstructive pulmonary disease (COPD). Haemodynamics and blood gases were studied at various inspiratory fractional concentrations of oxygen (FIO2): 0.15, 0.21, 0.30 and 1.0, randomly administered for 20 min periods under constant infusion of either placebo or almitrine (8 micrograms.kg-1.min-1) in 20 patients with COPD. The almitrine group exhibited a significant increase in mean pulmonary artery pressure, pulmonary vascular resistance and arterial oxygen tension (PaO2) at FIO2 0.15, 0.21 and 0.30. During hypoxia, the increase in mean pulmonary pressure and pulmonary vascular resistance was three times greater in the almitrine group than the placebo group. No significant difference in cardiac output and systemic haemodynamics was found. These results suggest that almitrine at the dose used, enhances pulmonary vasoconstriction in COPD patients.


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
N. P. Talbot, G. M. Balanos, P. A. Robbins, and K. L. Dorrington
Can intravenous endothelin-1 be used to enhance hypoxic pulmonary vasoconstriction in healthy humans?
Br. J. Anaesth., October 1, 2008; 101(4): 466 - 472.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
N. Dalibon, M. Moutafis, N. Liu, J.-D. Law-Koune, S. Monsel, and M. Fischler
Treatment of Hypoxemia During One-Lung Ventilation Using Intravenous Almitrine
Anesth. Analg., March 1, 2004; 98(3): 590 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. Moutafis, N. Dalibon, N. Liu, G. Kuhlman, and M. Fischler
The Effects of Intravenous Almitrine on Oxygenation and Hemodynamics During One-Lung Ventilation
Anesth. Analg., April 1, 2002; 94(4): 830 - 834.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. C. Body and S. K. Shernan
The Utility of Nitric Oxide in the Postoperative Period
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 1998; 2(1): 4 - 30.
[Abstract] [PDF]

Home page
 Mol. Pharmacol.Home page
J. R. López-López, M. T. Pérez-García, E. Canet, and C. Gonzalez
Effects of Almitrine Bismesylate on the Ionic Currents of Chemoreceptor Cells from the Carotid Body
Mol. Pharmacol., February 1, 1998; 53(2): 330 - 339.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the European Respiratory Society.